ANDEMBRY® received manufacturing and marketing approval in Japan on February 20, 2025, for the prevention of acute attacks in hereditary angioedema (HAE) ANDEMBRY® is the ...

KalVista's sebetralstat nears FDA approval as a first-in-class oral treatment for hereditary angioedema. Read here for an ...

Patients with hereditary angioedema who switched from other drugs to donidalorsen for long-term prophylaxis experienced fewer ...

Neurodegenerative diseases are a heterogeneous group of disorders that are characterized by the progressive degeneration of the structure and function of the central nervous system or peripheral ...

As KalVista Pharmaceuticals awaits an FDA decision on its hereditary angioedema (HAE) treatment sebetralstat, the company has ...

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that its wholly-owned subsidiary, KalVista Pharmaceuticals, Ltd ...

Target enrollment achieved in RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, strengthening confidence in clinical timelinesEnrollment underway in ...

The observation that some non-concussive impacts can have clinical implications is unsurprising given the widely accepted evidence that subclinical injury can lead to neurological deficits in other ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Haemonetics (NYSE:HAE) and the best and ...

Gallbladder disease includes inflammation, infection, stones or blockage of the gallbladder. The gallbladder is a sac located under the liver. It stores and concentrates bile produced in the liver.

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where Intellia Therapeutics, Inc. (NASDAQ:NTLA) stands against other best ...